Jason K Sicklick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9289671/publications.pdf

Version: 2024-02-01

117625 133252 4,130 108 34 citations h-index papers

59 g-index 6702 times ranked citing authors

109

109 all docs

109 docs citations

#	Article	IF	CITATIONS
1	Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nature Medicine, 2019, 25, 744-750.	30.7	443
2	Prevalence of $\langle i \rangle$ PDL1 $\langle i \rangle$ Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncology, 2018, 4, 1237.	7.1	214
3	Analysis of <i>NTRK</i> Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precision Oncology, 2018, 2018, 1-20.	3.0	201
4	Epidemiology of Gastrointestinal Stromal Tumors in the Era of Histology Codes: Results of a Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 298-302.	2. 5	190
5	NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1604-1612.	4.9	175
6	Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nature Communications, 2020, 11, 4965.	12.8	172
7	FGFR1 and NTRK3 actionable alterations in "Wild-Type―gastrointestinal stromal tumors. Journal of Translational Medicine, 2016, 14, 339.	4.4	167
8	<i>ARID1A</i> alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy., 2020, 8, e000438.		117
9	Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature, 2016, 534, 407-411.	27.8	114
10	Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma. JAMA Surgery, 2016, 151, 365.	4.3	102
11	Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clinical Cancer Research, 2018, 24, 6248-6256.	7.0	89
12	Diminished Survival in Patients with Bile Leak and Ductal Injury: Management Strategy and Outcomes. Journal of the American College of Surgeons, 2018, 226, 568-576e1.	0.5	84
13	GPR68, a protonâ€sensing GPCR, mediates interaction of cancerâ€associated fibroblasts and cancer cells. FASEB Journal, 2018, 32, 1170-1183.	0.5	83
14	Improved Perioperative Outcomes With Minimally Invasive Distal Pancreatectomy. JAMA Surgery, 2014, 149, 237.	4.3	81
15	Molecular Pathways: Targeting the Microenvironment of Liver Metastases. Clinical Cancer Research, 2017, 23, 6390-6399.	7.0	79
16	Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes. Annals of Surgical Oncology, 2016, 23, 134-141.	1.5	76
17	Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist, 2018, 23, 586-593.	3.7	7 5
18	Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. Journal of the American College of Surgeons, 2016, 222, 480-490.	0.5	71

#	Article	IF	CITATIONS
19	Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1. Gastroenterology, 2015, 149, 420-432.e16.	1.3	68
20	Targeting ARID1A mutations in cancer. Cancer Treatment Reviews, 2021, 100, 102287.	7.7	63
21	Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A populationâ€based study. Cancer, 2015, 121, 2960-2967.	4.1	60
22	TGF- \hat{l}^21 -mediated transition of resident fibroblasts to cancer-associated fibroblasts promotes cancer metastasis in gastrointestinal stromal tumor. Oncogenesis, 2021, 10, 13.	4.9	53
23	Single Agent and Synergistic Activity of the "First-in-Class―Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2016, 15, 2553-2562.	4.1	50
24	Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer and Metastasis Reviews, 2016, 35, 263-275.	5.9	49
25	Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA. Journal of Gastrointestinal Surgery, 2016, 20, 1132-1140.	1.7	48
26	Small bowel volvulus in the adult populace of the United States: results from a population-based study. American Journal of Surgery, 2015, 210, 201-210.e2.	1.8	47
27	Long-Term Health-Related Quality of Life after latrogenic Bile Duct Injury Repair. Journal of the American College of Surgeons, 2014, 219, 923-932e10.	0.5	46
28	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-na \tilde{A} -ve study. Genome Medicine, 2021, 13, 155.	8.2	44
29	The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. Journal of Surgical Research, 2014, 187, 377-385.	1.6	42
30	Outcomes after resection of cortisol-secreting adrenocortical carcinoma. American Journal of Surgery, 2016, 211, 1106-1113.	1.8	42
31	Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence. Annals of Surgical Oncology, 2016, 23, 126-133.	1.5	42
32	Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. International Journal of Cancer, 2021, 148, 702-712.	5.1	41
33	Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors. Journal of Gastrointestinal Surgery, 2013, 17, 1997-2006.	1.7	39
34	Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?. Annals of Surgical Oncology, 2016, 23, 708-713.	1.5	38
35	Curative Surgical Resection of Adrenocortical Carcinoma. Annals of Surgery, 2017, 265, 197-204.	4.2	38
36	Neutrophilâ€lymphocyte and plateletâ€lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2015, 112, 164-172.	1.7	36

#	Article	IF	CITATIONS
37	Actual 10â€year survivors following resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2016, 114, 971-976.	1.7	36
38	Cholecystectomy During the Third Trimester of Pregnancy: Proceed or Delay?. Journal of the American College of Surgeons, 2019, 228, 494-502e1.	0.5	33
39	Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors <i>via</i> GLI-mediated activation of <i>KIT</i> expression. Oncotarget, 2016, 7, 78226-78241.	1.8	29
40	MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages. Oncogene, 2019, 38, 5599-5611.	5.9	29
41	Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients. Journal of Gastrointestinal Surgery, 2017, 21, 352-362.	1.7	27
42	Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. Clinical Cancer Research, 2021, 27, 2792-2797.	7.0	27
43	Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor. Journal of Translational Medicine, 2014, 12, 41.	4.4	26
44	Surgical Management of Adolescents and Young Adults With Gastrointestinal Stromal Tumors. JAMA Surgery, 2017, 152, 443.	4.3	25
45	Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma. Journal of the American College of Surgeons, 2016, 223, 794-803.	0.5	24
46	Current management of succinate dehydrogenase–deficient gastrointestinal stromal tumors. Cancer and Metastasis Reviews, 2019, 38, 525-535.	5.9	23
47	Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. Oncogene, 2021, 40, 1957-1973.	5.9	22
48	Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens. JCI Insight, 2021, 6, .	5.0	20
49	International Surgical Residency Electives: A Collaborative Effort From Trainees to Surgeons Working in Low- and Middle-Income Countries. Journal of Surgical Education, 2014, 71, 694-700.	2.5	19
50	Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database. Annals of Surgical Oncology, 2018, 25, 2308-2315.	1.5	19
51	High prevalence of clonal hematopoiesisâ€type genomic abnormalities in cellâ€free <scp>DNA</scp> in invasive gliomas after treatment. International Journal of Cancer, 2021, 148, 2839-2847.	5.1	19
52	Development of a Soluble KIT Electrochemical Aptasensor for Cancer Theranostics. ACS Sensors, 2021, 6, 1971-1979.	7.8	19
53	Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns. Oncologist, 2021, 26, 787-796.	3.7	19
54	Academic Surgical Oncologists' Productivity Correlates with Gender, Grant Funding, and Institutional NCI Comprehensive Cancer Center Affiliation. Annals of Surgical Oncology, 2018, 25, 1852-1859.	1.5	18

#	Article	IF	Citations
55	Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors. JAMA Network Open, 2020, 3, e2013565.	5.9	17
56	Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma. Journal of Translational Medicine, 2019, 17, 246.	4.4	16
57	Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Longâ€Term Survival. World Journal of Surgery, 2016, 40, 706-714.	1.6	15
58	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. Annals of Surgical Oncology, 2018, 25, 520-527.	1.5	15
59	Diagnostic Accuracy of Preoperative Gadoxetic Acid–enhanced 3-T MR Imaging for Malignant Liver Lesions by Using Ex Vivo MR Imaging–matched Pathologic Findings as the Reference Standard. Radiology, 2015, 276, 775-786.	7.3	14
60	Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. International Journal of Cancer, 2020, 146, 3450-3460.	5.1	14
61	Duodenal-Jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic <i>NF1</i> and Notch Pathway Mutations. JCO Precision Oncology, 2017, 2017, 1-12.	3.0	13
62	A Novel <i>PRKAR1B-BRAF</i> Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 238-242.	4.9	13
63	Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity. Clinical Cancer Research, 2021, 27, 5334-5342.	7.0	13
64	Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance. Clinical Cancer Research, 2017, 23, 6733-6743.	7.0	12
65	Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group. American Surgeon, 2017, 83, 761-768.	0.8	12
66	Features of synchronous versus metachronous metastasectomy in adrenal cortical carcinoma: Analysis from the US adrenocortical carcinoma database. Surgery, 2020, 167, 352-357.	1.9	11
67	Anti-KIT DNA Aptamer for Targeted Labeling of Gastrointestinal Stromal Tumor. Molecular Cancer Therapeutics, 2020, 19, 1173-1182.	4.1	11
68	Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database. Annals of Surgical Oncology, 2021, 28, 6551-6561.	1.5	11
69	Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: Retrospective analysis of an International Patient Registry. Journal of Surgical Oncology, 2019, 120, 715-721.	1.7	10
70	KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor. Molecular Cancer Therapeutics, 2021, 20, 2035-2048.	4.1	10
71	Personalized, molecularly matched combination therapies for treatment-na Journal of Clinical Oncology, 2017, 35, 2512-2512.	1.6	10
72	Synchronous metastatic colon cancer and the importance of primary tumor laterality – A National Cancer Database analysis of right- versus left-sided colon cancer. American Journal of Surgery, 2020, 220, 408-414.	1.8	9

#	Article	IF	CITATIONS
73	Gastric Plexiform Fibromyxoma. Journal of Gastrointestinal Surgery, 2019, 23, 1936-1939.	1.7	8
74	The Use of Solicited Publishing by Academic Surgeons. Surgery, 2018, 164, 212-218.	1.9	7
75	Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. JCO Precision Oncology, 2022, 6, e2000508.	3.0	7
76	The prognostic significance of adrenocortical carcinomas identified incidentally. Journal of Surgical Oncology, 2018, 118, 1155-1162.	1.7	6
77	Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. Oncologist, 2020, 25, e1803-e1806.	3.7	6
78	Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary. JCO Precision Oncology, 2021, 5, 1687-1698.	3.0	6
79	Rapidly progressive subcutaneous metastases from gallbladder cancer: insight into a rare presentation in gastrointestinal malignancies. Journal of Gastrointestinal Oncology, 2014, 5, E58-64.	1.4	5
80	Porta Hepatis Mass. JAMA Surgery, 2016, 151, 187.	4.3	4
81	Precision oncology: the intention-to-treat analysis fallacy. European Journal of Cancer, 2020, 133, 25-28.	2.8	4
82	Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease. European Journal of Haematology, 2021, 107, 642-649.	2.2	4
83	Correcting the misnomers of epithelial–mesenchymal relations. Journal of Surgical Research, 2013, 182, 36-39.	1.6	3
84	Tumor Symbiosis: Gastrointestinal Stromal Tumor as a Host for Primary Peritoneal Mesothelioma. Journal of Gastrointestinal Surgery, 2019, 23, 879-881.	1.7	3
85	Moving gastrointestinal stromal tumours towards truly personalised precision therapy. Lancet Oncology, The, 2020, 21, 865-867.	10.7	3
86	Patient-Derived Sarcoma Organoids Offer a Novel Platform for Personalized Precision Medicine. Annals of Surgical Oncology, 2022, 29, 7239-7241.	1.5	3
87	Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma. Journal of Gastrointestinal Surgery, 2015, 19, 2154-2161.	1.7	2
88	Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process. Cancers, 2020, 12, 2375.	3.7	2
89	Commission on Cancer Facility Type is Associated with Overall Survival in Patients with Gastric Adenocarcinoma in the United States. Annals of Surgical Oncology, 2021, 28, 2846-2855.	1.5	2
90	A Solution to Academic Radiology's Experience With Solicitation E-mails From Predatory Journals. American Journal of Roentgenology, 2021, 216, 233-240.	2.2	2

#	Article	lF	CITATIONS
91	Molecular pathogenesis of biliary tract cancer. , 2017, , 150-159.e2.		1
92	Biomarkers of Bad Biology: Curse or a Blessing?. Annals of Surgical Oncology, 2019, 26, 318-320.	1.5	1
93	Synchronous, Yet Genomically Distinct, GIST Offer New Insights Into Precise Targeting of Tumor Driver Mutations. JCO Precision Oncology, 2021, 5, 525-532.	3.0	1
94	Fluorescence-guided laparoscopic hepatectomy. Annals of Laparoscopic and Endoscopic Surgery, 2016, 1, 10-10.	0.5	1
95	Analysis of over 100,000 patients with cancer for CD274 (PD-L1) amplification: Implications for treatment with immune checkpoint blockade Journal of Clinical Oncology, 2018, 36, 47-47.	1.6	1
96	Pregnancy-associated large pelvic desmoid tumor: A case report of fetal-protective strategies and fertility preservation. Gynecologic Oncology Reports, 2022, 39, 100901.	0.6	1
97	Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies. Npj Precision Oncology, 2022, 6, 18.	5.4	1
98	Co-Localization of Gastrointestinal Stromal Tumors (GIST) and Peritoneal Mesothelioma: A Case Series. Annals of Surgical Oncology, 0, , .	1.5	1
99	Pelvic Mass After Prostatectomy. JAMA Surgery, 2014, 149, 741.	4.3	0
100	ASO Author Reflections: Towards Better Metrics for Judging Academic Productivity in Surgical Oncology. Annals of Surgical Oncology, 2018, 25, 620-621.	1.5	0
101	Letter responds to comment on "intention-to-treat analysis in precision oncology: A cautious interpretation― European Journal of Cancer, 2020, 138, 228.	2.8	0
102	Consensus treatment guidelines for urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process Journal of Clinical Oncology, 2017, 35, 452-452.	1.6	0
103	A novel t-stage classification system for adrenocortical carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group Journal of Clinical Oncology, 2017, 35, 266-266.	1.6	0
104	Guidelines for management of urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process Journal of Clinical Oncology, 2017, 35, e15641-e15641.	1.6	0
105	RAS alterations: Next-generation sequencing of $1,526$ patients with diverse malignancies reveals prognostic and therapeutic correlates Journal of Clinical Oncology, 2018, 36, 12096-12096.	1.6	0
106	Investigation of profile-related evidence determining individualized cancer therapy (I-PREDICT) in heavily pre-treated patients: A role for combinatorial precision cancer therapy Journal of Clinical Oncology, 2018, 36, 2531-2531.	1.6	0
107	Re-visiting <i>EGFR</i> amplification as a target for anti-EGFR therapy: Analysis of cell-free circulating tumor DNA in patients with diverse cancers Journal of Clinical Oncology, 2018, 36, 12028-12028.	1.6	0
108	A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the U.S. Adrenocortical Carcinoma Study Group. VideoEndocrinology, 2018, 5, .	0.1	0